Search results

Page 1 of 12

Your search for Alzheimers returned 115 results

Order results by:
Download as a CSV:
Target: GPR3 (Class A Orphans)
Consequences of altering gene expression: implicated in Alzheimer's disease and is elevated in the sporadic Alzheimer's disease brain.
Consequences of altering gene expression: accumulation of the amyloid-beta peptide in vitro and in an Alzheimer's disease mouse model
Mutations/pathophysiology - disease: Alzheimer disease
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease
Mutations/pathophysiology - role: neurons and may be a potential therapeutic target for the treatment of Alzheimer's disease
Target: programmed cell death 1 (CD279) (Other immune checkpoint proteins, CD molecules)
Mutations/pathophysiology - disease: Alzheimer disease
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease
Mutations/pathophysiology - role: Alzheimer's disease anti-PD1 antibody treatment was used to induce immune checkpoint blockade. The biological
Receptor Immuno Comment: Alzheimer's disease (AD): In mouse models of AD anti-PD-1 antibody treatment was used
Target: presenilin 2 (A22: Presenilin)
Synonym: presenilin 2 (Alzheimer disease 4)
Mutations/pathophysiology - disease: Alzheimer disease 4
Mutations/pathophysiology - disease: Early-onset autosomal dominant Alzheimer disease aka Alzheimer disease 4
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease 4
Ligand: leucomethylthioninium
Comments: Alzheimer's disease (AD) and other tau-opathies. We believe this is the compound being
Clinical use: Alzheimer's Association International Conference in Toronto (July 2016) and reported on the NewScientist website
Mechanism of action: Alzheimer's plaques and filaments respectively. Inhibition of the formation of tau filaments/tangles is one strategy
Ligand: florbetaben
Comments: Alzheimer's disease (AD) . and are the two other PET reagents approved for Abeta detection
Clinical use: Abeta) as a diagnostic biomarker in the brains of patients with Alzheimer's disease (AD) .
Mechanism of action: Alzheimer's disease. The 18F radioactive tracer can then be detected by PET scanning and its accumulation
Ligand: flortaucipir (18F)
Comments: P10636) in Alzheimer's disease brains. Compare with the approved agent, , used to visualise beta-amyloid.
Clinical use: NCT02016560, in cognitively healthy volunteers and patients with mild cognitive impairment and Alzheimer's disease.
Bioactivity comments: Alzheimer's disease patients . Flortaucipir (18F) signal co-localises with beta-amyloid, but does not bind
Ligand: neflamapimod
Comments: compound is being repurposed since the p38alpha mechanism may modulate Alzheimer's specific inflammatory processes .
Clinical use: Alzheimer's disease in June 2015. These trials, NCT02423200 and NCT02423122, have now been completed
Immuno Ligand Comments: Alzheimer's disease, as predicted by preclinical assessment in a mouse model of the disease
Target: presenilin 1 (A22: Presenilin)
Mutations/pathophysiology - disease: Alzheimer disease 3
Mutations/pathophysiology - disease: Early-onset autosomal dominant Alzheimer disease aka Alzheimer disease 3
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease 3
Target: C5a1 receptor (Complement peptide receptors)
Mutations/pathophysiology - disease: Alzheimer disease
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease
Mutations/pathophysiology - comment: Alzheimer's disease. Inhbition of C5aR, through oral administration of PMX205, in these models reduces
Target: NLRP1 (NOD-like receptor family)
Comment: cancer , and evidence that suggests that NLRP1 and NLRP3 inflammasomes are activated in Alzheimer's disease .
Mutations/pathophysiology - disease: Alzheimer disease
Mutations/pathophysiology - disease: Alzheimer's disease aka Alzheimer disease

1 2 3 4 5 6 7 8 9 10 11 12

Target search page
Ligand search page
Pharmacology search page